How much revenue + tests-billed + payer-coverage + Medicare-ADLT + FDA-clearances/approvals + CAP-CLIA-ISO 15189 accreditations + biopharma-partnerships + clinical-utility-publications + guideline-inclusions + $ASP-per-test do AI Diagnostics/Pathology/Sequencing/Reference-Lab startups need for Series A in 2026?
Series A gate: $3-30M net-revenue OR 25k-500k tests-billed + 60-95% payer-coverage-of-lives (Medicare + 3+ commercial national + at least one BCBS + one Medicaid MCO) + at least one CMS ADLT-eligible OR Palmetto MolDx LCD (positive) OR NCD Next-Generation Sequencing coverage + one FDA 510(k)/De Novo/PMA (or PCCP-anchored AI/ML SaMD clearance under Aug-2024 guidance) OR FDA-CLIA LDT phase-2 compliance package per Apr-2024 Final Rule + CAP-15189 + CLIA-88 + ISO 15189 + HITRUST CSF v11.4 + SOC 2 Type II + one anchor biopharma companion-Dx deal (Roche/Genentech/AstraZeneca/BMS/Merck/Pfizer/GSK/Novartis/Sanofi/Lilly/J&J/Amgen/Regeneron/Bayer) + 3+ peer-reviewed clinical-utility publications (JCO/NEJM/Lancet/JAMA/Nature Med) + at least one NCCN/ASCO/CAP-ASCP-AMP/ACMG guideline inclusion + $500-$5,000 $ASP-per-test blended + at least one dated MDCG 2019-11 (EU IVDR) or MDSAP self-declaration if EU/UK/CA/AU/JP-bound. Cautionary comps: Invitae Ch-11 Jan-2024 $239M LabCorp asset-sale, NanoString-Bruker Ch-11 2024 $392M, Singular Genomics G4 shutdown Sep-2024, T2 Biosystems Nasdaq-delist Q2 2024, Grifols-Brookfield take-private collapsed Aug-2024, Illumina-Grail forced divest Jun-2024 $8B (EU-CMA+FTC+DOJ), Progenity-Preventice wound-down Q4 2023, NeoGenomics-Inivata wound-down Q1 2024, PacBio+Adaptive+Personalis+Guardant+Karius+Accelerate Diagnostics+10x+Akoya+Myriad+Exact Sciences Q3 2024 layoffs/restructures, ACLA vs FDA LDT lawsuit pending Aug-2024, CMS PAMA delays 2025, HIPAA Security Rule NPRM Dec-2024, EU IVDR compliance-extensions Jan-2024.
What are the specific traps around the FDA LDT Final Rule (Apr-2024), EU IVDR extensions (Jan-2024), CMS PAMA/ADLT/MolDX LCD, ACLA vs FDA lawsuit, and the HIPAA Security Rule NPRM (Dec-2024) that AI-Dx founders keep missing?
FDA LDT Final Rule Apr-2024 ends 47 years of enforcement discretion in 4 phases (May-2025 MDR/correction-removal, May-2026 registration/listing/labeling, May-2027 QSR/QMSR+ISO 13485, May-2028 high-risk PMA, Nov-2028 moderate-risk 510(k)/De Novo) — legacy LDTs signed off before May-2024 remain grandfathered but only if unchanged, and the ACLA vs FDA lawsuit (Aug-2024, E.D. Texas) may vacate the rule (AMP vs FDA cautionary). Product must ship PCCP-anchored AI/ML SaMD design controls per FDA Aug-2024 guidance not free-text change logs. EU IVDR 2017/746 phase-outs extended Jan-2024 to 2027 (Class D), 2028 (Class C), 2029 (Class B/A-sterile) — but the notified-body bottleneck is real (~14 IVDR NBs vs 50+ IVDD NBs) and MDCG 2019-11 performance-evaluation + MDCG 2019-16 cyber must be dossier-ready. CMS PAMA Final Rule reporting delayed to 2025 — labs cannot assume Medicare CLFS floor holds; MolDX Palmetto LCD (positive) is the practical gate for oncology molecular tests; CMS ADLT status yields a 3-quarter list-price payment window but revocation risk is real. HRSA 340B, HHS OIG AKS/Stark, EKRA, and Sunshine Act govern lab-clinician arrangements — pull-through economics that look like kickbacks will draw DOJ FCA scrutiny (BioReference, Genova, uBiome cautionary). HIPAA Security Rule NPRM Dec-2024 would mandate MFA + encryption-at-rest + annual pen-test + patch cadence + asset inventory — treat as effective now and build audit-trail against NIST SP 800-66. ONC HTI-1 Dec-2023 already requires DSI-transparency for predictive-DSI; HTI-2 Proposed Jul-2024 extends TEFCA and USCDI v5. Miss any and Series A investors will haircut ARR 40-60% for regulatory drag.
How do the Illumina-Grail forced divest (Jun-2024 $8B), Invitae Ch-11 (Jan-2024 $239M to LabCorp), Tempus AI IPO (Jun-2024 + Ambry $600M), Guardant Shield FDA (Jul-2024), Exact Cologuard Plus FDA (Oct-2024), and Danaher-Abcam ($5.7B 2023) reshape the 2026 Dx/Genomics cap-table?
Six catalysts have reset the 2026 cap-table: (1) Illumina-Grail forced divest Jun-2024 $8B — the EU-CMA/FTC/DOJ trifecta signals CFIUS/HSR scrutiny on any sequencer-plus-Dx vertical stack, so Series B/C narratives must decouple platform from clinical-lab pull-through. (2) Invitae Ch-11 Jan-2024 with $239M LabCorp asset-sale Feb-2024 — hereditary+carrier+onco-hereditary rollup thesis is dead; investors want unit-economics-first (positive contribution margin per test at $300-$800 ASP with reagent+labor+shipping+ADLT-arbitrage transparency). (3) Tempus AI $TEM IPO Jun-2024 (raised $410M at $6.1B enterprise value) + Ambry $600M May-2024 — establishes the AI-Dx+data-licensing dual-revenue comp (foundry $300-$500M ARR, insights $150-$300M ARR); founders now need dated biopharma-data-deal MSAs, not 'AI-ready dataset' claims. (4) Guardant Shield CRC screening FDA-approved Jul-2024 — first blood-based CRC screen at Grade B USPSTF-eligible; the 'screen vs Cologuard' narrative is now bimodal and $ASP for blood-CRC caps around $920 (Medicare). (5) Exact Cologuard Plus FDA-approved Oct-2024 — sensitivity/specificity upgrade defends the $EXAS moat but Q3 2024 restructure signals margin-compression. (6) Danaher-Abcam 2023 $5.7B + Danaher-IDT+Cepheid+Aldevron+Beckman + Thermo-Olink $3.1B Oct-2023+CorEvitas $912M 2023 + Bio-Techne+Agilent-BIOVECTRA $925M Nov-2023+CytoNet Aug-2024 = life-tools consolidation has withdrawn 8+ comps and biased exits to strategic acquirers not IPO. Founders should model (a) $ASP compression 20-40% against blood-tumor-normal MRD comps (Signatera+Reveal+NeXT Personal+Tracker), (b) reg-package cost $20-$60M for FDA PMA/De Novo AI/ML SaMD PCCP-anchored, (c) 3-5 anchor biopharma deals with milestone+royalty+data-license triple, (d) Palmetto MolDx LCD + Medicare ADLT + BCBS TEC + Aetna/UHC/Cigna PA within 18 months of launch, and (e) HITRUST CSF v11.4 + SOC 2 Type II + ISO 42001 + HIPAA Security Rule NPRM + EU AI Act Annex III audit-trail from day one to be acquirable by Roche/Thermo/Danaher/Illumina/Abbott/Siemens/BD tech-Dx practices.
